{"id":984,"date":"2019-12-20T11:58:45","date_gmt":"2019-12-19T22:58:45","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=984"},"modified":"2019-12-20T11:58:45","modified_gmt":"2019-12-19T22:58:45","slug":"slides-from-edinburgh","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=984","title":{"rendered":"Slides from Edinburgh"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_custom_heading]Slides form Edinburgh[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]Why are Online Communities a Good Idea?[\/vc_custom_heading][vc_column_text]<\/p>\n<ul>\n<li>A new diagnosis can be a scary, and lonely, time.<\/li>\n<li>Online communities like CLLANZ, HealthUnlocked, and Patient Power are helping people come together, and cope with complex chronic illnesses such as CLL.<\/li>\n<li>The patients\u2019 shared experiences and knowledge of their condition, hospitals, healthcare services and drugs is leading to improvements in patient care, both by themselves, and by their carers, and their doctors.<\/li>\n<li>Knowledgeable patients become their own advocates and ask questions of their doctor, forming a partnership approach.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_custom_heading]Chronic Lymphocytic Leukaemia[\/vc_custom_heading][vc_column_text]<\/p>\n<ul>\n<li>Most common adult leukaemia<\/li>\n<li>Most patients are older than 65<\/li>\n<li>Cancer of the immune system affecting B-cells<\/li>\n<li>Can present with a weak immune system<\/li>\n<li>Each patient\u2019s CLL is different<\/li>\n<li>Most patients will, often initially, not require treatment. Watch and wait (and worry)<\/li>\n<li>Most new therapies have improved the prognosis of CLL, but it still remains a chronic condition that can only rarely be cured<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_custom_heading]Initial Workup of CLL Patients[\/vc_custom_heading][vc_column_text]<\/p>\n<ul>\n<li>All patients at diagnosis<\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">-Flow cytometry (via blood and \/ or bone marrow) to confirm CLL diagnosis<\/p>\n<ul>\n<li>Informative for prognosis and \/ or therapy determination<\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">-Del17p, and del11q.\u00a0 These portend for more aggressive disease<\/p>\n<p style=\"padding-left: 40px;\">-Mutated \/ unmutated VH gene status assessment (not yet available in New Zealand).<\/p>\n<p style=\"padding-left: 40px;\">-No CT scan unless symptoms are present:\u00a0 PET scan can be helpful if Richter\u2019s suspected<\/p>\n<ul>\n<li>Bone marrow biopsy and aspirate not necessary in absence of cytopenias<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The combination of two targeted therapies \u2014 ibrutinib (Imbruvika, Pharmacyclics\/Janssen) and venetoclax (Venclexta, AbbVie) \u2013 has shown impressive results in the front-line treatment of chronic lymphocytic leukemia (CLL).<\/p>\n","protected":false},"author":1,"featured_media":410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/07\/Neil-Graham_video.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=984"}],"version-history":[{"count":2,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/984\/revisions"}],"predecessor-version":[{"id":986,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/984\/revisions\/986"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/410"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}